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Abstract 
 
There has been an increased interest aiming to the conception of delivery 
systems to encapsulate, protect and release lipophilic active compounds such as 
vitamins. In this particular case vitamin D, which numerous studies both in vitro and in 
vivo had already shown the ability to inhibit cell proliferation in several cell types, 
including carcinomas of the breast, prostate, colon, skin, brain and myeloid leukemia 
cells. Furthermore, has also been demonstrated that vitamin D may potently induce 
apoptosis and inhibit angiogenesis and also tumor invasion and metastases.  
In this study nano-scale drug delivery systems using polymeric nanoparticles 
and liposomes were developed to incorporate vitamin D increasing its bioavailability for 
cancer therapy anticancer drug. The polymeric matrix was prepared with poly(lactic-co-
glycolic acid) (PLGA) which is FDA approved and is often employed in drug deliver 
due to its biocompatible and biodegradation properties. The produced PLGA 
nanoparticles were stable within the size range of 170-180 nm, low polydispersity 
index, negative zeta potential and spherical shape observed by TEM. The 
PLGA/vitamin D nanoparticles had shown an encapsulation efficiency of approximately 
75%. For this carrier system, the in vitro cytotoxic studies were performed on human 
pancreatic duct cell line (HPNE). The PLGA/vitamin D nanoparticles showed to have 
reduced cytotoxic effect on these cells comparing to vitamin D free. 
The liposomal system composed of 1-plamitoyl-2-oleoyl-sn-glyceo-
phosphocholine (POPC) presented a mean size of 77 nm and zeta potential between -6 
and 0 mV. The encapsulation efficiency for vitamin D resulted in approximately 67%. 
Also physical stability tests were performed for over 3 weeks which proved to be a 
reliable system to protect the drug content. In conclusion, both systems presented 
promising results that lead to the continued research of the vitamin D encapsulation on 
these selected nanocarriers.   
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1 Introduction 
1.1 Motivation 
 
Liposoluble compounds like vitamins are commonly found in food or used as 
excipients in the well-known industries such as pharmaceutical, cosmetics or even in the 
food industrial field. Vitamins are very sensitive compounds to manage, so they need to 
be protected of the environmental conditions that may affect their chemical integrity and 
their physiological effects.  
The existing solution is their encapsulation that allows preserving their native 
properties for longer. These encapsulation systems are developed at nano-scale in order 
to improve shelf life time, to an active control of the delivery compound and prevent the 
existence of side effects. Regarding the different administration pathway, liposoluble 
vitamins may imply different requirements on their use.  
Vitamin D is a good example as it is liposoluble and its major functions are the 
increase of intestinal absorption of calcium and promotion of normal bone formation 
and mineralization. It is already evidenced that vitamin D is of great importance and is 
associated with a wide range of diseases, such as cardiovascular diseases, diabetes, 
rickets, osteoporosis, osteomalacia and secondary hyperparathyroidism and cancer. 
Several studies demonstrated that vitamin D may potently induce apoptosis and inhibit 
angiogenesis and also tumor invasion and metastases (Field & Newton-Bishop, 2011). 
Vitamin D is present in two main chemical forms, namely, ergocholecalciferol or 
activated ergosterol or vitamin D2 and cholecalciferol or activated 7-dehydrocholesterol 
or vitamin D3.  
 
 
1.2 Main Objectives 
 
Nowadays the attempts to engineer efficient local and targeted drug release 
agents are mainly focused on nanoparticle systems. In order to overcome the water 
solubility limitation of the vitamin D is necessary to develop a suitable delivery system. 
Encapsulation techniques through controlled release and small doses administration are 
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able to reduce the hypervitaminosis syndrome and the possible appearance of side 
effects. The main strategies available to formulate liposoluble vitamin carriers are lipid 
based formulations, where vitamins are solubilized in a matrix entrapment by polymer. 
The objective of this work is to design and develop nanocarriers capable of 
encapsulating vitamin D3 to be tested as anticancer drug.  The selected nanosystems 
were PLGA nanoparticles and liposomes. These systems were characterized and 
evaluated as nanocarriers of vitamin D for its delivery into pancreatic normal cells. 
Few studies about these systems have been published for vitamin D.  
To our knowledge, any study was developed on vitamin D-loaded PLGA 
nanoparticles for its controlled release into cancer cells. 
 
 
 
1.3 Thesis Organization 
 
This thesis is divided in 5 chapters each associated to the following content. 
Chapter 1, which is the present chapter, explains the main motivations to 
formulate and develop nanocarriers for Vitamin D. Additionally, the main objectives of 
this work are defined.  
Chapter 2 presents the state of the Art. It induces the properties of vitamin D and 
its biological functions, and its relation with cancer, the studies that have been 
developed so far on the vitamin D encapsulation, in particular for nanoparticles and 
liposomes as drug delivery vehicles. 
Chapter 3 presents the materials, and methods used throughout the work. 
Specifically preparation of PLGA nanoparticles and liposomes as well as the principles 
of the physicochemical characterization of the nanoparticles. The description of the 
cytotoxicity studies was also included. 
In Chapter 4 includes the main obtained results and their further discussions for 
the PLGA and liposomal systems developed for the encapsulation of vitamin D.  
The overview of this study, its main conclusions and additional future 
perspectives are presented on Chapter 5. 
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2 State of the Art 
2.1Vitamin D  
 
Vitamin D is a liposoluble molecule and its major functions are the increase of 
intestinal absorption of calcium and promotion of normal bone formation and 
mineralization (Gueli et al., 2012). Vitamin D has two main chemical forms, vitamin D3 
(cholecalciferol) or vitamin D2 (ergocalciferol) (Henry, 2011) (Wiseman, 1993). The 
chemical structures are shown in figure 1. 
 
 
 
 
 
 
 
 
 
Figure 1 – Chemical structure of vitamin D2 (A) and vitamin D3 (B) (University of Bristol, 2007). 
 
Vitamin D needs to bind to a receptor, known as the vitamin D receptor or VDR, 
which allows the connection to its genetic effects, and also have been identified in 
several tissues and cells (Field & Newton-Bishop, 2011). This vitamin is considered a 
steroid hormone and is synthesized in human skin from 7-dehydrocholesterol in the 
presence of UV. Firstly the vitamin D that enters in the human body through skin or by 
ingestion in the diet is still biologically inactive. It requires two obligate hydroxylations, 
first in the liver to 25-hydroxyvitamin D, and then in the kidney to 1.25-
dihydroxyvitamin D (M. F. Holick, 2006). Vitamin D travels in the blood bounded to an 
α-globulin and is present in two main chemical forms, namely ergocholecalciferol or 
activated ergosterol or vitamin D2 and cholecalciferol or activated 7-dehydrocholesterol 
or vitamin D3 (Gueli et al., 2012). Vitamin D3 is synthesized in the skin after light 
Carrier systems for Vitamin D 
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exposure and displays several chemical structures, such as calciol that is the non-
hydroxylated and inactive form. Another variation is calcidiol or 25-hydroxyvitamin D, 
which is the monohydroxylated and the blood circulating form that is responsible for 
several different actions related with the control of calcium and phosphorus 
homeostasis, internal transport, bone metabolism and renal calcium re-absorption, as 
well as the task to control the blood pressure and insulin secretion (Gonnet et. al. 2010).  
The metabolized structures of the vitamin D inside the body are presented in the figure 
2. 
 
Figure 2 – Chemical structure of; A) cholecalciferol; B) calcifediol; C) calcitriol (University of Bristol, 2007). 
 
Besides that, in enterocytes, calcidiol regulates calcium and phosphorous 
absorption by its attachment with its cellular receptor. The other main chemical form 
known is the vitamin D2 which is formed by the action of the UV irradiation with 
ergosterol (Gonnet et al., 2010).  
More precisely the action of cholecalciferol is important to regulate the 
concentrations of calcium and phosphate ions in the blood serum. Also has a relevant 
function in skeletal homeostasis, either by controlling bone metabolism by regulation of 
the osteoblast differentiation, proliferation and apoptosis. Still, plays an important role 
in the expression of specific bone proteins and growth factors in the upcoming forming 
bone tissue (Ignjatovic et. al. 2013). On the other, ergocalciferol is synthesized in 
plants. Although its susceptible to oxidation and is also isomerized to isotachysterol in 
the presence of light and under acidic conditions (Patel & San Martin-Gonzalez, 2012). 
Cholecalciferol and ergocalciferol are equally effective as inhibitors of lipid 
peroxidation, since they have the same side chains as cholesterol and ergosterol 
(Wiseman, 1993). Additionally, important information is asserted by the work of 
Wiseman (1993), where cholecalciferol, 1.25-dihydrocholecalciferol, ergocalciferol and 
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7-dehydrocholesterol may act as membrane oxidants through the membrane 
stabilization against lipid peroxidation with the interaction between their hydrophobic 
rings (Wiseman, 1993).  
The supply of vitamin D is affected by several factors, such as the geographic, 
seasonal, genetic factors and some diseases that will disturb the metabolism and others 
that cause bad levels of absorption (Kimlin et al., 2007). It has been estimated that 1 
billion people worldwide have vitamin D deficiency or insufficiency (Michael F. 
Holick, 2009). Vitamin D deficiency or insufficiency happens mainly in developing 
countries and can cause rickets (Rajakumar, 2003).  
The main source of vitamin D for most of the population comes from the sun 
exposure with a small amount acquired from food and supplements (Heaney et. al. 
2003). 
Vitamin D3 is the preferable form of vitamin D (Armas et. al. 2004). 
Additionally, the usual indicator of the vitamin D status in the body is the vitamin D3 or 
25 (OH) D. Moreover, this metabolite has the advantage of longer half-life time, 
approximately 3 weeks, when compared to other vitamin D metabolites. The vitamin D3 
status is determined through measurements in the plasma or serum (Deeb et. al. 2007).  
Epidemiological studies suggest an important role in autoimmune diseases, 
infections, cardiovascular disease and cancer (Woloszynska-Read et. al. 2011). 
A relationship between vitamin D and cancer does exist and is strongly 
supported by epidemiological, clinical and laboratorial studies (Mocellin, 2011). 
Several cancers may be vitamin D sensitive such as brain, breast, bladder, colon, rectal, 
endometrial lining, esophagus, gallbladder, kidney, lungs, ovaries, pancreas, prostate 
and stomach since they express the 1-α-hydroxylase that is indispensable to convert 25 
(OH) D into 1,25 (OH) D (M. F. Holick, 2006). One possible explanation is that 1.25-
dihydroxyvitamin D3 appears as a regulator of gene expression and signal transduction 
in every tissue. Besides that, the presence of functional VDR in human tumors and 
cancer cell lines may be indicated as target for drug delivery therapy since those cell 
lines may be capable of transform the compound into his active form (Welsh, 2012). 
This information allows assuming that vitamin D might be connected with growth 
mechanism of these different types of cells. 
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For the next chapters of this work, cholecalciferol may be referred also as 
Vitamin D. 
 
 
2.2 Nanocarriers for Vitamin D 
 
Vitamin D is a highly lipophilic molecule that cannot be directly dispersed into 
an aqueous solution. Instead, it needs to be incorporated into an appropriate colloidal 
system prior to dispersion (Gonnet et al., 2010). In order to explore for targeting 
purpose and also to improve his bioavailability is necessary to review the carrier 
systems to perform a sustainable release (Li et. al. 2011).  In the literature review, there 
is some lack of information regarding the nano or micro encapsulation of vitamin D3.     
Nevertheless, there are some studies referring the use of cholecalciferol and calcitriol in 
drug delivery. Furthermore, several case studies report the attempts that have been done 
in the matter of carrier systems referring as vitamin D3 and its metabolites as main drugs 
for carrier design systems. A few number of papers portraits the microencapsulation of 
cholecalciferol as a drug model or as a nutrient supplementation. Still, in another 
research study, it was described the encapsulation of cholecalciferol into hydrophobic 
alginate nanoparticles for sustained release form (Li et al., 2011).  In the work of Luca 
et. al. to enhance the viability and function of the pancreatic islet cell, cholecalciferol 
was encapsulated into cellulose acetate microspheres and tested as an anti-oxidizing 
agent (Li et al., 2011). Other formulation was presented by Nguyen et. al. where were 
used calcitriol loaded micro-particles using poly(vinyl-neodecanoate-crosslinked-
ethyleneglycol dimethacrylate) as polymer with the purpose to ensure the extension 
behaviour of the anti-cancer concentration after local hepatic injection (Nguyen et al., 
2007).  
Another carrier system proposed was vitamin D3 as a nutraceutical model for 
sustained release purpose and it is based on oleoyl alginate ester. The results obtained 
reveal that when the vitamin D concentration was increased it enabled the increase of 
loading capacity, but in the meantime the loading efficiency was descendent. Although, 
these nanoparticles were able to release vitamin D when located in the target, so it is 
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possible to pronounce positively that the oleoyl alginate ester nanoparticle is a sustained 
carrier system for vitamin D (Li et al., 2011). 
Recently a study developed by Almouazen et. al. displays the link between 
vitamin D3 and anticancer application. In this case, was carried out a formulation of 
vitamin D3, with metabolites cholecalciferol and calcitriol, using polymeric 
nanoparticles. These nanoparticles were used as carrier system and also studied to 
evaluate the in vitro treatment behaviour. In more detail, PLA was used as 
biodegradable polymer and it was concluded that these nanoparticles had shown an 
antiproliferative activity for over 10 days against breast cancer (Almouazen et. al. 
2013).  
 
 
2.3 Encapsulation of Hydrophobic Drugs 
 
 Encapsulation technology is the process to capture active agents into a carrier 
material, as a way to improve and protect bioactive molecules for further delivery 
(Nedovic et. al. 2011). 
The clinical utility of most conventional chemotherapeutics is limited either by 
the inability to deliver therapeutic drug concentrations to the target tissues or by severe 
and harmful toxic effects on normal organs and tissues (Drummond et. al. 1999). 
  The advantages of encapsulating drugs in nanocarriers comprise an increase in 
the dissolution rate of hydrophobic or drugs with poor solubility, the surface properties 
allows target delivery and immune system evasion, controlled and sustained drug 
release. When these factors act together provide less drug dosing frequency and 
improve the therapeutic effect extending in vivo therapeutic half-life (Cheow & 
Hadinoto, 2011) (Cho et. al. 2008). The ideal drug delivery system approach is the one 
that act on the selected target. Although the nanoscale drug delivery systems may act on 
the target by two strategies. The active strategy is where the carrier system possesses the 
specific ligand for the existing receptor in the target tissue. The other strategy relays on 
the passive targeting, where the carrier system moves to the inflamed tissues and release 
the drug in providing higher concentration on site without induce toxicity (Malam et. al. 
Carrier systems for Vitamin D 
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2009). Even though, some authors suggest the importance of active targeting strategy 
due to the specific molecules conjugated at the surface of the carrier. These vector 
molecules recognize the overexpression of biomarkers in cancer cells enhancing the 
affinity for the delivery of the drug carrier at the specific site (Karra & Benita, 2012). 
Another important feature is the ability to avoid the recognition of the P-
glycoprotein, which is one of the main drug resistance mechanisms by the attachment to 
the specific receptors to pass in into the cell (Larsen et. al. 2000). Therefore, 
nanotechnology may cause a significant impact on drug delivery (Farokhzad & Langer, 
2009). The drug loading allows the optimization parameters in controlled drug delivery 
(Speiser, 1991). By encapsulation of potential drugs inside nanocarriers it is possible 
intensify their therapeutic index by enhancing their release time and also their 
pharmacokinetic profile. Besides the solubility and the stability of the drug is enhanced 
(Langer, 1998). Vitamin D is lipo-soluble thus it is essential to increase the solubility in 
water (Li et al., 2011). 
In this work, to encapsulate vitamin D was firstly necessary to select an 
appropriate delivery system. Depending on the hydrophobic nature of vitamin D, a 
hydrophobic polymer matrix is crucial to the drug loading succeed (Makadia & Siegel, 
2011). In that order PLGA is identified as primary choice. Polymers like PLGA have 
the benefit of biodegradability and biocompatibility (Danhier et al., 2012). The 
application of PLGA as outcome successfully as biodegradable polymer resultant of the 
monomers lactic acid and glycolic acid derived from its hydrolysis (Kumari et. al. 
2010). Besides, in other studies PLGA show competence to encapsulate drugs of poor 
solubility (Liu et. al. 2010). PLGA-based nanoparticles have the advantage of 
controlling the drug release by the extra time that they remain in the blood circulation 
resulting in the increase of the anti-tumor activity (Averineni et al., 2012). Furthermore, 
the polymer matrix offer rigidity to the overall structure making them more stable than 
liposomes (Pinto-Alphandary et. al. 2000). PLGA-based nanoparticles are colloidal 
systems and the separation of the encapsulated from the non-encapsulated nanoparticles 
is executed by centrifugation. Through this process is not so easy to fully control the 
accurate determination of the drug content. Another disadvantage that is related to the 
PLGA-based nanoparticles is the high initial burst release of the drug which might be 
due to the existence of drug adsorbed to the nanoparticle surface. Several studies had 
shown that when the nanoparticles are inside the body, there is a change in their 
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structure. This is the result of the complex interaction verified between the nanoparticles 
and the biological systems and the behavior change (Danhier et al., 2012) (Kumari et 
al., 2010). To minimize these pitfalls, another drug delivery system was studied and 
characterized for vitamin D, to accomplish a better understanding of the advantages and 
drawbacks of both systems.  
Liposomes or phospholipid vesicles are introduced as drug carrier system where 
it seems that are widely investigated in such applications. They are nontoxic and non-
immunogenic lipid molecules and are able to encapsulate hydrophobic molecules in 
lipid bilayers given them the capacity to deliver oil-soluble compounds (Storm & 
Crommelin, 1998). In liposomal formulations, physicochemical properties as surface 
charge, functionality or size are well controlled by adding or mixing commercially 
available lipid molecules. This is advantageous over other carriers which need 
additional chemical modifications to change their structure. Nonetheless, physical and 
chemical limitations had been noted especially in cancer therapy due to oxidation and 
hydrolysis of the phospholipids molecules causing drug loss, short residence time in 
blood and even alterations in size caused by aggregation and fusion (Lasic, 1998) (Stark 
et. al. 2010). Nevertheless, the biocompatibility at cellular level is higher in liposomes 
when compared to some of the nanoparticles formed by the synthetic polymers (Y. Liu 
et al., 2010). 
As drug delivery systems used currently liposomes and nanoparticles are the 
primary choice for the rational delivery at nano-scale (Malam et al., 2009) (Y. Liu et al., 
2010).  
For this work, there have been proposed two systems to comprehend and to test 
the advantages reported in the literature and to understand their interaction with vitamin 
D.  
 
 
2.3.1 Polymeric-based Nanoparticles as Carriers 
 
Nanoparticles are usually defined as solid colloidal particles that can be prepared 
by both polymerization methods and combined with preformed polymers (Vauthier & 
Bouchemal, 2009). These particular systems may be relevant as active vectors for its 
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ability to release drugs. Its subcellular size allows a higher intracellular uptake and at 
the same time can be biocompatible with tissues and cells when combined with 
materials which embody biodegradable and biocompatible characteristics (Mora-
Huertas et. al. 2010).  
Due to the particular environment of the tumor site the use of nanoparticles can 
influence the cancer therapy by the accumulation of a higher drug concentration at the 
site. In addition, the possible side effects of the chemotherapeutic agents are reduced 
(van Vlerken & Amiji, 2006). Moreover, it can be added imaging contrast agents to 
these nanoparticles that facilitate the overview to their address to the specific site 
(Parveen et. al. 2012). 
Other benefits that may be mentioned are the high drug encapsulation efficiency, 
protection against factors as pH, light and the reduction of tissue irritation due to the 
action of the protective polymer coating. Also the low polymer content compared to 
other systems nano-systems such as nano-spheres (Pinto Reis et. al. 2006). 
Polymeric nanoparticles already support an extensive background as drug 
carriers especially in the pharmaceutical field, where the main aspects that need to be 
analyzed are mean size, zeta potential, encapsulation efficiency, active release, nano-
dispersion stability and in vivo and in vitro pharmacological performance behaviors 
(Mora-Huertas et al., 2010).  
Currently the synthetic polymers in use are polylactide (PLA), poly D, L-lactide-
co-glycolide (PLGA) and polyethylene glycol (PEG) and the biological polysaccharides 
are chitosan, cyclodextrin and dextrans (Chan et al., 2009). Besides, synthetic polymers 
already have their formulations and methods of production well described and adapted 
to several types of drugs such as hydrophobic or hydrophilic and also to small 
molecules or macromolecules. Still, they provide protection of drug from degradation, 
the possibility to modify the surface properties, and also the possibility of better 
interaction with biological materials and the ability to reach the specific organs or cells 
(Danhier et al., 2012). Some examples of compounds constituted by polymeric 
nanocarriers as chemotherapeutics agents are given by Cho et. al. (2008) such as 
Abraxane, Xyotax, CT-2106, PK1 and PK2 (Cho et al., 2008). 
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2.3.2 Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Polymer 
 
Biodegradable polymers may be derived from natural or synthetic origins and 
are synthesized in vivo, either enzymatically or non-enzymatically or both, in order to 
produce biocompatible, toxicologically safe by-products which are further eliminated by 
the already existing metabolic pathways (Makadia & Siegel, 2011). In the category of 
synthetic biodegradable polymers used in drug delivery is included the poly lactic-co-
glycolic acid (PLGA), which is the one to be used in this particular work and is already 
widely used as drug delivery vehicle. For this specific polymer some requirements are 
applied, where biocompatibility is one of the clearly relevant properties. This property 
is related to the biological environment and also to the tolerability that exists in the 
interaction of the specific drug-polymer tissue (Shive & Anderson, 1997). The 
parameters that are going to be directly involved with the successful fate of the 
polymeric nanoparticles are mainly the size, size distribution, surface charge, drug 
encapsulation efficiency among others (Feng, 2004). Controlling the size of the PLGA 
nanoparticles is very important because is necessary to adjust drug-polymer complex 
and also imaging agents can be incorporated in order to achieve imaging probes of the 
cancer drug targeting (Kumari et al., 2010). The zeta potential is the indicator of the 
surface charge which will play an important role on the interaction with the charge of 
membrane cells (Hans & Lowman, 2002). Moreover, small volume and high viscosity 
are the targets to accomplish if higher encapsulation efficiency is desired (Maa & Hsu, 
1997) (Yeo & Park, 2004). It is currently observed for polymeric nanoparticles that an 
increase of the polymer concentration will cause an increase in the encapsulation 
efficiency value. This can be explained by the higher viscosity and fast solidification 
rate achieved by the increase of polymer concentration which leads to lower porosity 
preventing the drug diffusion from polymer channels and thus a low initial burst release 
(Yeo & Park, 2004). 
PLGA is a FDA approved polymer and non-toxic, which is a copolymer of poly 
lactic acid (PLA) and poly glycolic acid (PGA). It is already well defined, in respect to 
design and performance, and PLGA is an acronym for poly D, L–lactic-co-glycolic acid 
where D- and L-lactic acid forms are in equal ratio (Danhier et al., 2012). The 
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hydrolysis of these monomers in water originating glycolic acid and lactic acid that will 
forward be eliminated through the Kreb’s cycle (Lu et al., 2009).  
PLGA is soluble with several common solvents as chlorinated solvents, 
tetrahydofuran, acetone or ethyl acetate. For example in water, PLGA is degraded by 
hydrolysis of its ester linkages (Makadia & Siegel, 2011). 
Additionally, PLGA is one of the most employed carriers for sustained drug 
release, where it is possible to control relevant parameters such as polymer molecule 
weight, ratio of lactide to glycolide and drug concentration to achieve the desire dosage 
upon the drug type (Mohamed & van der Walle, 2008). The release of the incorporated 
drug molecule and surface erosion are due to the change of the physical properties of 
PLGA. Those physical properties previously studied, are linked with several factors 
such as initial molecular weight, the ratio of lactide to glycolide, the size of the carrier, 
exposure to water, surface change and storage temperature (Houchin & Topp, 2009). As 
basic standard, higher content of PLGA leads to faster rates of degradation, yet with the 
exception of 50:50 ratio of PLA/PGA which exhibits the higher degradation interval. 
This is due to the presence of methyl side groups in PLA that enables more 
hydrophobicity properties than PGA, where in the other hand with higher lactide 
content PLGA copolymers are less hydrophilic, which leads to absorb less water 
resulting in a slowest degradation rate. Another important consideration is the molecular 
weight and polydispersity index that are directly associated with the mechanical 
strength of the PLGA (Makadia & Siegel, 2011). Yet, the PLGA composition and 
molecular weight were related with nanoparticle size, where nanoparticles with 50:50 
PLGA achieve a lower mean size when compared to 75:25 PLGA (Konan et. al. 2002). 
PLGA carriers allow the release either by diffusion through the polymer barrier, or by 
erosion of the polymer, or by a combination of both mentioned mechanisms (Shive & 
Anderson, 1997). However has been studied that the release is assumed to be biphasic, 
where initially by diffusion and later by degradation or erosion of the polymer matrix 
itself (Panyam et al., 2003). 
Furthermore, PLGA carriers tolerate the modification of their surface to direct 
the delivery to tumour or even other tissues (L. Liu et al., 2004). 
For the preparation of PLGA nanoparticles, the most common method is the 
emulsification-solvent evaporation technique, which has been successfully applied for 
hydrophobic drugs (Hans & Lowman, 2002). The hydrophobic nature of PLGA allows 
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hydrophobic molecules as cholecalciferol to be adsorbed by hydrophobic interactions 
(Kerleta, 2010).  
This technique allows the encapsulation of hydrophobic drugs by the dissolution 
of the polymer and the active compound in an organic solvent, in this particular case 
ethyl acetate as usually is the first option (Mora-Huertas et al., 2010). The existing oil 
(O) in water (W) emulsion or O/W is prepared by adding water and surfactant, here is 
Pluronic® F127, to the polymer solution. Pluronic® F127 is constituted by copolymers 
arranged in A-B-A structure where is comprehended as ethylene oxide-propylene oxide-
ethylene oxide. Additionally Pluronic® F127 enhances solubility, helps the metabolic 
stability and also enables remaining more time in the blood stream (Batrakova & 
Kabanov, 2008). The successfully incorporation of Pluronic® F127 is due to the 
hydrophilic–lipophilic balance (HLB) values of the ethylene oxide-propylene oxide-
ethylene oxide derivatives and the availability of the carrier matrix (Santander-Ortega 
et. al. 2006). 
 Regarding the external phase, the solvent used is water and PLGA is chosen as 
the stabilizing agent. In order to obtain better dispersion stability, stabilizer agents may 
be used in the diluted solutions, thus the dilution phase is a mixture of water with 
Pluronic® F127. Then the nano-sized droplets are accomplished by sonication or 
homogenization. Still for the preparation of nano-particle, the organic phase is 
emulsified under vigorous agitation in the aqueous phase which results in the 
evaporation of the organic solvent. After the waiting time of that step, the solvent is 
evaporated and the nanoparticles are collected after centrifugation. Furthermore, it has 
been studied that the nano-particle size is correlated to the shear rate used previous in 
the emulsification process, the chemical composition of the organic phase, the polymer 
concentration, the drop size and also the oil-to-polymer ratio (Moinard-Chécot et. al. 
2008).   
Other example that focuses the advantages of polymeric nanoparticles as drug 
delivery systems is the work by Musumeci et. al. where the aim of the work was to 
improve the drug solubility in a delivery system for the intravenous administration of 
docetaxel, which shows poor water solubility. Polymeric nanoparticles were prepared 
using as matrix PLA and PLGA, at different molecular weights, where in the final 
results they conclude that system was able to entrap the docetaxel and also to provide a 
sustained drug release (Musumeci et al., 2006). Is found in literature that PLGA 
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nanoparticles are considered as valued carrier system for the encapsulation of several 
anti-cancer agents as well as paclitaxel, 9-nitrocamptothecin, cisplatein, triptorelin, 
dexamethasone, xanthone, etc. (Danhier et al., 2012) (Hans & Lowman, 2002). 
 
 
2.3.3 Liposomes as Carriers 
 
Liposomes are micro-scale spherical vesicles constituted by phospholipids, 
which enclose liquid compartments within their structure of lipid bilayers. Besides, they 
are able to encapsulate both hydrophilic and lipophilic materials (Hsieh et. al. 2002). 
Liposomes are widely employed as nano-carriers, and are very attractive 
vehicles because of its interaction with the host cell due to the use of phospholipids that 
are the main structural component of the membranes (Khan et. al. 2008) (Cheow & 
Hadinoto, 2011). The incorporation of the drug into liposomes is achieved by several 
mechanisms as formation with an aqueous solution saturated with the soluble drug, 
through the use of organic solvents and solvent exchange mechanisms, by the use of 
lipophilic drugs, and with pH gradient methods (Y. Liu et al., 2010). Furthermore, the 
incorporation of the water soluble drugs is in the aqueous core on the other hand the oil 
soluble compounds are entrapped in the liquid bilayer (Cheow & Hadinoto, 2011). The 
liposomal lipid bilayer along with the mentioned properties have the ability to minimize 
toxic side-effects that are usually associated with the use of chemotherapeutic agents 
(Khan et al., 2008). 
  As advantages, the liposomes can be produced on a large scale and are 
composed of well tolerated components (Müller et. al. 2002). Also they are widely used 
due to high biocompatibility, friendly pharmacokinetic profile and the flexibility 
available of surface modification by variation of the preparation methods (Torchilin, 
2005) (Y. Liu et al., 2010). Moreover, they provide the attractive biological property to 
deliver pharmaceutical purpose inside individual cellular compartments (Torchilin, 
2005). 
Liposomes, mainly constituted by phospholipids, may be used in either active or 
passive targeting strategies. They get into the interstitial space from the bloodstream and 
are very useful because of his competence to receive additional molecules in the 
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external surface of the lipid bilayer becoming easier to manipulate them (Malam et al., 
2009). Additionally, liposomes provide the possibility to use ligands as targeted 
nanotechnology-based drug delivery systems. This system excludes the need of the 
conjugation of drugs into the targeting ligand which might affect negatively both the 
target molecule and the drug (Backer et. al. 2002). However, if the receptor/ligand 
recognition is disrupted it automatically results in the complete loss of activity of the 
drug (Backer et al., 2004) (Khan et al., 2008).  
In this study liposomes were prepared using the modified thin film hydration 
technique (Szoka & Papahadjopoulos, 1980). This technique is commonly used in 
laboratory preparations and implicates three major steps during the production such as 
vesicle formation, vesicle size reduction and purification. This technique consists in the 
lipid dissolution in an organic solvent as chloroform, where afterwards this solvent is 
removed under small pressure vacuum evaporation leading to the formation of a thin 
film. The composition of the liposomes used is mainly based in phosphatidylcholine 
(PC) and cholesterol (Drummond et al., 1999). The incorporation of hydrophobic 
cholecalciferol is through dissolution with the lipids (Wagner & Vorauer-Uhl, 2011). 
After, the thin film is hydrated with phosphate buffer solution (PBS) where 
multilamellar vesicles (MLV) are formed. To obtain small unilamellar vesicles (SUV), 
extrusion of the hydrated lipid films is performed using different filter pore sizes under 
several cycles. This method is advantageous because allows to obtain high 
encapsulation percentage of lipophilic substance (Lasic, 1998). After that, the 
information about liposomes behavior in biological environment and also in storage 
conditions is effect of parameters such as the size, surface charge, and chemical 
composition, among others. Besides the surface charge will influence directly the 
physical stability since the fusion and/or aggregation of liposomes might happen if they 
are not characterized (Lasic, 1998). Thus in the present study liposomes were 
characterized in terms of particle size, surface charge, encapsulation efficiency and 
stability during storage time.  
Currently, several preparation methods of lipid-based systems are under clinical 
trials for some cancer drugs (Cho et al., 2008). Those liposome formulations for 
chemotherapeutic delivery are already available for human use such as Doxil® which 
has successful result, that is normally used to treat cancer in AIDS-related Kaposi 
sarcoma and multiple myeloma, Mycet, DaunoXome, Depocyt (Malam et al., 2009) 
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(Torchilin, 2005). Another interesting point that has been under development in this 
particular system is the potential to overcome the multidrug resistance that is usually 
associated with cancers, whereas with that resistance the liposomes efficiency is 
reduced. While liposomes have showed good results with the Doxil®, new formulations 
are been explored (Malam et al., 2009). Drug loading efficiency for water-soluble 
antibiotics such as gemtamicin has low values, meaning low drug-lipid ratio. On the 
other hand, the use of hydrophobic drugs might induce some delay in the drug release 
rate (Xu et. al. 2007). 
 Several chemotherapeutic drugs have been use in liposomes either in vitro or in 
vivo as well as paclitaxel, methotrexate, PALA, vincristine, vinblastine, AraC, 
topotecan, vinorelbine, daunomycin, doxorubicin and cisplatin (Drummond et al., 
1999). 
Moreover, in the work of Frankenberger et. al. (1997) was tested the possibility 
of entrap 1.25-vitamin D3 compounds in liposomes to target myeloid leukaemia cells. 
That possibility was due to the development that liposomes were taken by 
myelomonocytic cells in various organs. They show that the use of liposomes to deliver 
1.25-vitamin D3 compounds might be a real possibility as consequence of the in vitro 
results obtained (Frankenberger et al., 1997). 
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3 Materials and Methods 
 
3.1 Chemicals 
 
Poly (D,L-lactide-co-glycolide) (PLGA, Resomer® RG 503 H lactide:glycolide 
50:50, acid terminated MW 24-38 kDa), Pluronic ® F127 and ethyl acetate were 
purchased from Sigma-Aldrich (St. Louis, USA). Cholecalciferol (MW 394,65 kDa) 
was purchased from Alfa Aesar (Karlsruhe, Germany). Uranyl Acetate (dehydrate, MW 
424,146 kDa).  
1-palmitoyl-2-oleoyl-sn-glyceo-phosphocholine (POPC, MW 760,1 g/mol) was 
purchased from Avanti Polar Lipids, Inc (USA). Cholesterol (C27H46O, 99%), 
Phosphate buffer solution (PBS, pH 7.4) and EPC-Rhodamine (MW 1249,65 g/mol) 
were purchased from Sigma-Aldrich (St. Louis, USA). Chloroform (MW 119,38 g/mol) 
was purchased from Merck (Germany).  
All aqueous solutions were prepared in deionized and filtered ultrapure Milli-Q 
water (Milli-Q Academic, Millipore, France).  
 
3.2 Formulation of PLGA Nanoparticles 
 
The technique for the preparation of PLGA nanoparticles was the 
emulsification-solvent evaporation method (Danhier et al., 2012). The masses of PLGA 
(10 mg) without and with cholecalciferol (1.0 mg) were dissolved in ethyl acetate 
solution (0.100 mL). An aqueous solution of 1% (w/v) Pluronic® F127 (0.200 mL) was 
added dropwise to the organic phase. The emulsion was then sonicated under ice bath. 
The mixture was placed into 2.5 mL of 0.1% (w/v) Pluronic® F127. The next step 
comprises magnetic stirring at 800 rpm for 3 hours at room temperature to fully 
solubilize the oil phase with the aqueous phase. After the evaporation of the organic 
solvent, the emulsion is filtered (0.2 µm) to exclude aggregates. The emulsion is stored 
Carrier systems for Vitamin D 
19 
 
at 4 ºC during overnight at final concentration of 1 mg/mL, to help in the consolidation 
of the physical structure of the nanoparticles. The bare and the cholecalciferol-loaded 
nanoparticles formed a pellet after the centrifugation (14.500 rpm, 30 min) and were re-
suspended in ultrapure water. The same procedure is followed for the unloaded 
nanoparticles preparation.   
 
3.3 Preparation of Liposomes 
 
Liposomes were prepared by the thin lipid film hydration method. In this study, 
POPC was used for conventional liposome preparation (Szoka & Papahadjopoulos, 
1980). Liposomes were prepared with the mixed lipid content of POPC, Cholesterol, 
rhodamine with molar ratios of 52:45:3 mixed in organic solvent chloroform to assure a 
homogeneous mixture. Rhodamine is selected because its emission wavelength is higher 
than for vitamin D and for its fluorescence. In order to prepare liposomes with 
cholecalciferol, a stock solution was prepared. Stock concentration was 0.63 mM. To 
evaporate the organic solvent is used a dry nitrogen stream forming a lipid film. Lipid 
solution was kept overnight through vacuum desiccation pump until a thin lipid film 
was observed and all of organic solvent was evaporated. The dried lipid film was 
hydrated with 2 mL phosphate buffer solution (PBS). The suspension was vortexed (15 
min) and kept in a sonicator bath for 15 minutes. The vesicle suspension was then 
extruded through Whatman filters of decreasing size (up to 50 nm pore size membranes) 
using a pressure extruder apparatus running in discontinuous mode. The suspension is 
then extruded by multiple cycles. Desalting column (PD-10 Sephadex) was used to 
change buffers and remove the free cholecalciferol from the liposomes. The total lipid 
concentration was 0.01 M.  
 
3.4 Physicochemical Characterization 
 
The size, polydispersity index, zeta potential and morphological appearance 
were the parameters used to characterize the produced nanoparticles and liposomes. 
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3.4.1 Particle Size Distribution 
 
Dynamic light scattering (DLS) is a very useful technique for the measuring of 
size, size distributions and in some cases the shapes of nanoparticles in liquids. This 
technique is targeted to measure hydrodynamic properties such as the translational 
and/or rotational diffusion coefficients, which are then related to sizes and shapes via 
theoretical relations. This technique is based on the intensity of a light scattered into a 
dispersion of particles with a given scattering angle. The particles in a solution are in 
Brownian motion, and when the light is sent through causes a fluctuation in the 
intensity. Thus, this intensity fluctuation is measured due to the real-time calculation of 
the scattered intensity time correlation function. For spherical monodisperse particles, 
the Stokes-Einstein relation relates the translational self-diffusion coefficient to the 
particle radius R; 
  
   
    
                                                                                      
 
where kB is the Boltzmann constant, T the absolute temperature and η the 
viscosity of the suspending medium. 
Also, the nanoparticle dispersions are usually polydisperse, in the measure cell. 
It is possible to assume that may be a distribution of particles with several sizes and 
shapes (Pecora, 2000). 
The particle size and polydispersity index (PdI) were measured by DLS with a 
ZetaSizer Nano ZS (Malvern Instruments, Worcesterchire, UK), using a clear 
disposable zeta cell at approximately 25 ºC and an angle of the laser incidence 173º. 
The results obtained from measurements of each batch were expressed in triplicate.  
 
3.4.2 Zeta Potential 
 
All particles in suspension exhibit a zeta potential, or surface charge which is 
result of the ionization of the surface groups or adsorption of charged species. Besides 
size and concentration of particles are key parameters to the measurements. In a 
solution, the movement of the particles through solution due to an applied voltage, 
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where at same distance from every particle exists a boundary, which the ions do not 
move with the particle. This potential is defined as zeta potential (𝜁). The zeta potential 
is crucial to understand the stability of a colloidal suspension. The electrophoretic 
mobility is the used technique to measure the zeta potential, where an electric field is 
applied which induces charged particles to move. By measuring the electrophoretic 
mobility of a particle, the zeta potential may be calculated using the Henry equation; 
 
   
  𝜁     
  
                                                                                      
 
Where UE is the electrophoretic mobility,   is the dielectric constant, 𝜁 the zeta 
potential, η the viscosity and f(ka) the Henry’s function, which for aqueous medium and 
moderate electrolyte concentration is considered 1.5. In that case, the zeta potential can 
be determined from the electrophoretic mobility measured by the Smoluchowski 
equation; 
 
𝜁  
   
 
                                                                                      
 
The suspension is considered stable if it presents a zeta potential higher than 30 
mV in modulus. If this value is between -30 and 30 mV, the system is considered 
unstable because when it is weakly charged there is no force to prevent the particles to 
aggregate (Sze et. al. 2003).  
The zeta potential of the nanoparticles is assessed using the dynamic light 
scattering (DLS) with ZetaSizer Nano ZS (Malvern Instruments, Worcesterchire, UK). 
All the determinations were performed in a clear disposable zeta cell at approximately 
25 ºC and a light scattered at an angle of 17º.  The results were obtained in triplicate for 
each measurement.  
 
3.4.3 Morphologic Analysis 
 
Transmission Electron Microscopy (TEM) is a microscopy technique that uses a 
beam of electrons instead of light to observe the specimen. When the beam of electrons 
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interacts with the atoms in a sample, two types of scattering resulted from the incidence, 
as elastic and inelastic scattering. Then, the electrons are emitted by a source and are 
focused and magnified by a system of magnetic lens. Also, the electrons that are 
elastically scattered are the transmitted beams, which are the ones that pass through the 
objective lens. The objective lenses are the responsible to produce the image for the 
microscope (Voutou & Stefanaki, 2008). 
The morphology of the nanoparticles is observed by TEM. For the following 
experiment, a sample of 10 µL of the solution PLGA/vitamin D3 is placed into a copper 
TEM grid (Formvar/Carbon on 400 mesh Cu (50) from Agar Scientific). After drain out 
the excess fluid at room temperature, the grid is stained with 2% (v/v) uranyl acetate. 
The samples were air-dried and examined using a transmission electron microscope at 
an accelerating voltage of 80kV. The images are observed on a TEM Yeol Yem 1400 
(80kV) (Tokyo, Japan) with a Digital Camera Orious 1100 (Japan). 
 
3.5 Cholecalciferol Loading/Encapsulation 
Efficiency 
 
Encapsulation efficiency (EE) is defined as the percentage of the mass of drug 
encapsulated in the polymeric carrier relative to the initial amount of drug added during 
the preparation (Li et al., 2011). The vitamin D encapsulation efficiency (EE) of PLGA 
nanoparticles was calculated by the equation 4. 
 
       
                                            
                    
                        
 
Due to the modification of the initial protocol to produce the nanoparticles by 
the solvent-evaporation method, the samples are suspended from the agitation and then 
they were centrifuged at 14,500 rpm for 30 minutes using a MiniSpin Plus (Eppendorf). 
The samples were centrifuged to remove the extra PLGA and the loaded vitamin D. 
Then the absorbance of the supernatant was measured, using a dilution factor (5x). On 
the other hand, the measurement of cholecalciferol content in liposomes was performed 
by UV – 1700 PharmaSpec UV-Vis spectrophotometer from Shimadzu (Japan). Firstly, 
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the unloaded cholecalciferol was separated from liposomes through Sephadex PD-10 
desalting column. In order to verify the location of vitamin, several aliquot of liposomal 
suspensions were diluted with phosphate buffer solution (PBS) at pH 7.4. Then, to 
apply the dilution ratio 1:4 for liposomes and ethanol to achieve the disruption of the 
liposome structure, enabling the release the drug into the solution. The solution is used 
to measure the absorbance at 265 nm. Drug content was estimated according to the 
following equation (Hazra et. al. 2005). 
 
       
                                                                      
                                                                       
                   
 
 
3.6 Stability of Liposomes 
 
Generally, for the lipids used to manufacture liposomes is necessary to establish 
the storage conditions and the shelf life time (uniformity of size distribution and 
minimal structural degradation) (Lasic, 1998). Furthermore, the physical stability of 
liposome is due to the integrity and the size distribution of the lipids. Besides, 
liposomes are susceptible to fusion, aggregation, and leakage of the drug substance 
during storage (Stark et al., 2010). To evaluate the physical stability of liposomes with 
regard to the retention of the loaded content, daily observation of size, polydispersity 
index, and zeta potential were assessed for the integrity and size of the liposomes and 
vitamin D loaded. The liposomal systems were maintained at 4 ºC during the storage 
period (du Plessis et. al. 1996). 
 
3.7 Cytotoxicity Studies 
 
Immortalized human pancreatic duct epithelial cells (hTERT-HPNE) were 
maintained in DMEM with 10% fetal bovine serum (FBS) under 5% CO2 humidified 
atmosphere at 37 ºC. The hTERT-HPNE cells were seeded in 96-well plates at a density 
of 10
4
 cells/mL, for a period of incubation of 24 hours. The cells were then treated for 
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48 hours with vitamin D and PLGA/vitamin D nanoparticles at the concentrations 
ranging between 0.001 and 100 nM. After the incubation period (48 hours) for the 
samples of nanoparticles and free vitamin D, cell viability was determined by PB and 
SRB assays. In order to study the cytotoxic effect of the incubations, the following 
assays PrestoBlue
TM
 (PB) cell viability reagent (Invitrogen, USA) and protein-binding 
dye sulforhodamine B (SRB) were used. The PB reagent, when added to the cells is 
modified by the reduced environment of the viable cells turning red in colour to became 
highly fluorescent, where it can be measured by fluorescence measurement at 560/590 
nm. As the SRB assay is used to estimate the cell density and the drug-induced toxicity 
by the measurement of cellular protein content. For PB assay, 50 µL of PB reagent, 
diluted 1:10 in DMEM, was incubated in each well for 45 minutes, at 37ºC in 
humidified atmosphere with 5% CO2, followed by the fluorescence reading (excitation 
at 560 nm and emission at 590 nm) using a microplate reader (PowerWave HT 
Microplate Spectrophotometer, BioTek). On the SRB method, the cells were fixed in 
situ with 50 µL of PBS and 25 µL of TCA for 1 h, in refrigerator. After the incubation 
period, cell monolayers were washed and stained with 50 µL of SRB dye for 30 
minutes. After washed repeatedly with 1% (v/v) of acetic acid to remove the excess dye 
and dried, the protein-bound dye is dissolved in 10 mM Tris base solution for 
absorbance determination at 560 nm using a microplate reader (PowerWave HT 
Microplate Spectrophotometer, BioTek). Concentration-response curves using non-
linear regression analysis were obtained and the inhibiting cell survival by 50% (IC50) 
was determined. IC50 is defined as the drug concentration needed to kill 50% of the 
incubated cells in a designated time period (Skehan et al., 1990; Vichai & Kirtikara, 
2006). 
 
3.8 Statistical Analysis 
 
Data were calculated with the mean and standard deviation. Student’s two-sided 
t-tests were performed to compare data sets using p-values (P<0.05) to determine 
statistically significance (McDonald, 2009). 
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4 Results and Discussion 
 
4.1 PLGA/cholecalciferol system 
 
A detailed study was developed in order to optimize the adequate conditions of 
the physicochemical characteristics of the bare PLGA and PLGA/cholecalciferol 
nanoparticles prepared by the emulsion-solvent evaporation technique. Consequently, 
the influence of the sonication time a critical step in the emulsion procedure to define 
the size of the nanoparticles was analyzed. The methodology for the encapsulation of 
cholecalciferol in the PLGA nanoparticles was also optimized. 
The in vitro cytotoxic effects on a human normal pancreatic cell line upon its 
treatment with PLGA/cholecalciferol nanoparticles were assessed, comparatively to the 
free cholecalciferol.  
 
 
4.1.1 Characterization of PLGA nanoparticles 
 
The nature and volume of the organic and the aqueous phase, as well as the 
properties and employed surfactant and polymer concentrations provide important 
consequences in the size distribution of nanoparticles. These parameters were already 
optimized by our group for the PLGA nanoparticles (Frasco et. al. 2012). 
Likewise, the intensity of the shear rate of the homogenization step helps to 
determine the final mean diameter size of the nanoparticles (Moinard-Chécot et al., 
2008).     
PLGA nanosized particles were induced by sonication. The sonication time was 
evaluated for 1 and 5 min. In these conditions, the physicochemical properties of the 
PLGA nanoparticles are summarized in Table 1. The sonication time is important to 
accomplish a good emulsion and also the formation of smaller sized particles 
(Mainardes & Evangelista, 2005). This step was performed in a sonication bath, with 
ice to avoid suspension overheating because excessive temperature heating can cause 
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substantial liquid evaporation resulting in changes to the sonication volume, or the 
degradation of the formulation components (Jwala et al., 2011). Thus, the effectiveness 
of the applied sonication conditions can be mainly evaluated by the results attained in 
the particle size distribution. The slightly reduction of the average particle size and 
polydispersity are indicative of a more effective dispersion. Although the statistical 
results had shown there for all parameters the difference was not significant (P > 0.05). 
It was decided to use a sonication time of 5 minutes for the following experiments. The 
mean PLGA nanoparticles sizes obtained were concordant when compared to values 
found in the literature are approximately 200 nm (Moinard-Chécot et al., 2008). 
Additionally, zeta potential measurements confirmed the negative values due to the use 
of non-ionic surfactant Pluronic® F127 and the presence of polymer terminal 
carboxylic groups. Zeta potential negative values are expected for PLGA nanoparticles 
due to the existence of the polymer terminal carboxylic groups. Moreover, when the 
range values are between -25 mV and -30 mV it is normally to expect good colloidal 
stability. This is explained by the high energy barrier that exists between the particles in 
suspension (Mora-Huertas et al., 2010).  
 
 
Table 1 – Physicochemical characterization of the bare PLGA nanoparticles, with different sonication time 
Data represented as mean ± SD (n=3).  
Sonication 
Time 
PLGA NPs 
Mean 
Diameter (nm) 
PdI 
Zeta Potential 
(mV) 
1 min 176 ± 2 0.10 ± 0.09 -34 ± 4 
5 min 172 ± 4 0.06 ± 0.04 -38 ± 3 
 
 
The single emulsion solvent evaporation method (Danhier et al., 2012) allowed 
the encapsulation of vitamin D. The size, polydispersity index and zeta potential values 
for bare and cholecalciferol-loaded PLGA nanoparticles are presented in Table 2. 
 
 
 
Carrier systems for Vitamin D 
28 
 
Table 2 – Physicochemical characterization of the bare PLGA and cholecalciferol loaded nanoparticles, 
with 5 min sonication time. Data represented as mean ± SD (n=3). 
PLGA NPs 
Mean Diameter 
(nm) 
PdI 
Zeta Potential 
(mV) 
Bare/unloaded 176 ± 4 0.04 ± 0.01 -40 ± 0.3 
Cholecalciferol-
loaded 
185 ± 6 0.08 ± 0.04 -29 ± 4.0 
 
The size and the polydispersity index increased for the cholecalciferol loaded 
nanoparticles when compared with the bare PLGA nanoparticles, but the differences are 
not significantly different (P > 0.05). It is assumed that the slightly increase on mean 
diameter value was due to the inclusion of cholecalciferol. The single emulsion solvent 
evaporation method had already shown high efficiency for the loading of lipophilic 
drugs (Dinarvand et. al. 2011).  When cholecalciferol is added to the nanoparticles it 
can be adsorbed in the surface and cause a small decrease in the zeta potential value. 
However, the values for zeta potential are concordant with literature leading to a stable 
colloidal dispersion (Mukherjee et. al. 2008). The same explanation is valid for the 
slight increase of mean diameter. These parameters play an important role for 
determining, the future drug release behaviour, specially their small size to avoid the 
capture from phagocytes retaining their presence in blood circulation  (Dinarvand et. al. 
2011). Moreover, PLGA possess negative charges and is stabilized in the process with 
the emulsifying agent Pluronic® F127 as already demonstrated (Mura et al., 2011). 
These stabilization mechanisms are function of DLVO interactions and also due to the 
role of hydration forces of the surfactant (Santander-Ortega et al., 2006). Pluronic® 
F127 amphiphilic character has the capacity to establish interactions with hydrophobic 
surfaces and even with biological membranes. Although it cause negatively charged 
nanoparticles confirmed by their value bringing stabilization to the colloidal system. 
Also steric repulsion by adsorption at the nanoparticles surface and the existence of the 
polymer terminal carboxylic groups helps to maintain the negatively charged surface 
(Mura et al., 2011). This relationship between PLGA nanoparticles and Pluronic® F127 
his advantageous because may neutralize the acidic environment resulted from the 
polymer degradation and might help in the drug interaction with the PLGA (Santander-
Ortega et al., 2006). Also, these results are in agreement with the transmission electron 
microscopic (TEM) images (Figure 3). 
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 4.1.2 Vitamin D encapsulation efficiency 
 
Drug encapsulation efficiency analysis was carried out in triplicate and 
expressed as percentage of drug in the produced nanoparticles with respect to initial 
amount (mg) used for the formulation of PLGA nanoparticles. The vitamin D 
entrapment efficiency was found to be 74 ± 8%. 
Regarding the values for encapsulation efficiency for emulsion-solvent 
evaporation technique are approximately 80%, the range values presented are similar to 
those founded in literature (Mora-Huertas et al., 2010). Moreover, in the work of 
Almouazen et. al. PLA nanoparticles for cholecalciferol entrapment were prepared with 
the nanoprecipitation technique, and high values of encapsulation efficiency were 
achieved (Almouazen et al., 2013).  
It can be observed that higher mean diameter may result in high quantity of 
cholecalciferol entrapped. However due to the experimental procedure, some polymer 
loss can be assumed resulting in the variation of the mean size diameter registered. This 
is due to the loss of organic solvent or even some polymer. Also the higher mean 
diameter observed in the table 2 is probably due to the slightly change in the diffusion 
of the organic solvent caused by removal of Pluronic® F127 and then originating larger 
particles. On the other hand, if the Pluronic® F127 volume is in the suspension that 
could be one of the reasons to decrease the nanoparticless mean diameter size making 
them more stable. The reason is that smaller particles have higher surface area/volume 
ratio which becomes an advantage for drug encapsulation (Zhang & Feng, 2006). 
Moreover, higher absolute values of zeta potential indicate strong repulsive forces 
among the particles to prevent aggregation in the medium (Mu & Feng, 2002). Besides, 
EE might increase due to the effect of the Pluronic® F127 which can help to 
accumulate the drug in the hydrophobic core (Lin et. al. 2005).  
It can be assumed that the formation of the nanoparticles with the diffusion 
method depends on several parameters. Namely, the concentration of the liposoluble 
compound in the organic phase which is capable of alters the mean diameter of the 
nanoparticles. The polymer concentration can also modify the thickness of the 
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nanoparticle membrane. Still, the volume used can also influence directly in the final 
mean diameter size of the NPs (Guinebretière et. al. 2002). Therefore is crucial to 
control the key aspects of the experimental process (Y. Liu et al., 2010).    
 
 4.1.3 Morphologic Analysis 
 
The morphologic examination of the nanoparticles was performed by TEM. The 
obtained images for formulations of bare and cholecalciferol-loaded PLGA 
nanoparticles are shown in Figure 3. 
 
 
 
 
 
 
 
 
Figure 3 - TEM micrograph of free (A) bare  PLGA and (B) PLGA/cholecalciferol nanoparticles. 
 
The PLGA nanoparticles were found to be spherical in shape with nano-sized 
range. The dark shadow in the image is probably due to some Pluronic® F127 residues 
that are still present from the separation of the pellet from the supernatant. Besides, the 
diameter determined by this method is ranged between 170 and 180 nm, which is 
supported by the size measurement performed by DLS.  
 
 
4.1.4 Cytotoxicity Studies 
 
The in vitro cytotoxic studies of PLGA/vitamin D formulations were performed 
on immortalized human pancreatic duct cells (HPNE) cells. The nanoparticles were 
tested and compared to free vitamin D using PB and SRB assays. The attained results 
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are presented in figure 4 and they show the decrease effect in cell survival after 48 h of 
exposure. This study was appreciated to evaluate the behavior of the interaction of 
vitamin D and PLGA/vitamin D nanoparticles with the cells viability. The results 
obtained by PB method are in figure 4A and the results by SRB method are in figure 
4B. 
 
 
Figure 4 – Viability of HPNE exposed to vitamin D free and PLGA/vitamin D: (A) determined by PrestoBlueTM 
assay; (B) determined by Sulforhodamine B assay. 
 
The results show the relationship between the vitamin D and PLGA/vitamin D 
nanoparticles concentration (nM) and cell viability (%). Several studies had shown the 
higher drug cytotoxicity due to the nano-encapsulation technique which is able to 
increase the cellular uptake (Wong et. al. 2007). The results also reveal that both 
PLGA/vitamin D and vitamin D alone had substantial toxic impact to cells after 48h 
exposure. It is observed the similar behavior for both assays and they are no 
significantly different from each other (P>0.05). Although it is noted a different 
behavior for the concentration 500 nM since the drug is encapsulated and the values are 
higher when compared to the vitamin D alone. This substantial toxic impact is 
important because non-tumoral cells are used in this study. However to better 
understand the role of NP uptake by the cells, further fluorescent microscopy studies 
needed to be performed. Nonetheless, the goal of this study was to evaluate the 
cytotoxic behavior of the vitamin D in in vitro studies. 
 The obtained IC50 values by both methodologies (PB and SRB) are concordant with 
each other and presented on the table 3. 
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Table 3 - Concentration of PLGA/vitamin D and vitamin D free required killing 50% of HPNE cells. Data 
represented as mean ± SD (n=3). 
Nanoparticles 
IC50 (nM) 
PB SRB 
Vitamin D 631 ± 43 851 ± 16 
PLGA/vitamin D 661 ± 31 512 ± 27 
 
These complementary quantitative assays reveal that these nanoparticles inhibited 
the cell viability. While a major difference is obtained by SRB method, where higher 
values of cell survival are registered causing a higher value of IC50, these results might 
be explained by the controlled release of the PLGA nanoparticles after cellular uptake 
related with the delayed therapeutic effect of the drug. In the PB method lower vitamin 
D free value is observed when compared with the presence of PLGA/vitamin D 
nanoparticles. To obtain lower cytotoxicity, higher concentration of vitamin D to 
encapsulate is needed to report a cell death rate of 50%. Moreover, for HPNE cells it is 
advantageous that less cytotoxicity is achieved. The IC50 values of both methodologies 
are not significantly different (P > 0.05) meaning they are concordant with each other. 
In accordance with literature, in medicine the cytotoxicity only should revealed in low 
concentration in the range of 10
-4
 and 10
-5
 M. In the same order if the value of IC50 is 
higher than 10
-4
 M is assumed that the toxic effect is increased to tissues and healthy 
organs (Bojat V., 2011). Several studies agreed that the in vitro active substance release 
behavior depends on a group of parameters such as such as the concentration and 
physicochemical characteristics of the active substance, solubility, the nature 
degradability, molecular weight and concentration of the polymer solid matrix when re-
precipitated, the nature of oil compound, nanoparticle size. Likewise depends on the 
conditions of the in vitro release test as medium pH, temperature, contact time and 
conditions of the preparation method (Mora-Huertas et al., 2010). However, further 
studies need to be performed to elucidate the in vitro and in vivo cytotoxicity of this 
system. So far, in vivo studies for delivery of vitamin D were not found in literature. 
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4.2 Liposomes/cholecalciferol System 
 
A different encapsulation system, based on liposomes as carrier vehicle was 
tested to find favourable formulations for cholecalciferol. It is well studied that several 
anticancer drugs had already been incorporated into liposomes, for example liposomal 
doxorubicin (Drummond et al., 1999). This system contributes for higher therapeutic 
efficacy at low dosage, higher biological half-life and also provides stability against 
enzymatic degradation (Elbayoumi & Torchilin, 2010). The physicochemical properties 
as size and lipid composition are the essential factors of stability and in vivo behavioural 
of liposomes (Harashima et. al. 1995). Hence was performed a characterization study to 
comprehend the interaction that vitamin D might cause when is incorporated into 
liposomes. For this work liposomes were prepared by modified thin film hydration 
technique. Further size homogenization was achieved by extrusion technique which 
avoids the application of high temperatures and shear stress forces that could damage 
the liposomal structure (Stark et al., 2010).  
 
 
4.2.1 Characterization of liposomes and Vitamin D encapsulation 
efficiency 
 
The results of the sizes, polydispersity index and zeta potential of the unloaded 
and cholecalciferol-loaded liposomes are presented in the table 4. 
 
Table 4 – Physicochemical characterization of unloaded and cholecalciferol-loaded liposomes. Data 
represented as mean ± SD (n=3). 
Liposomes Mean diameter (nm) PdI Zeta Potential (mV) 
Unloaded 77.1 ± 0.6 0.09 ± 0.01 -6 ± 2 
Cholecalciferol-loaded 78.4 ± 0.2 0.11 ± 0.01 0.4 ± 0.2 
Carrier systems for Vitamin D 
35 
 
 
The size distribution and zeta potential value of liposomes unloaded and 
cholecalciferol-loaded are significantly not different (P > 0.05). However, in the case of 
the cholecalciferol-loaded liposomes, the mean diameter value has the tendency to be 
higher due to the location of the cholecalciferol in the hydrophobic area of the bilayer 
that increases the liposome packing. The size distribution is an important parameter for 
liposomes due to the drug accommodation and also for the recognition in the blood 
circulation enabling the uptake by the mononuclear phagocytic system (MPS) (Hupfeld 
et. al. 2006). The mean size of liposomes is determined by the selected pores of the 
extrusion technique which does not degrade the phospholipids and even can increase the 
encapsulation efficiency (Olson et. al. 1979). The presented measurements were 
obtained after the decreasing filter pore sizes, and as expected with the application of 
the smaller pore size (50 nm) resulted in a liposomal formulation with smaller mean 
diameters (77-78 nm).   
 The zeta potential of the liposomes is approximately zero, thus confirming the 
neutrality of POPC (Cohen & Khorosheva, 2001). Although some minimal change in 
the value is detected that may be attributed to the aggregation or fusion of some 
liposomal particles. Also with the application of potential, the liposomes are more 
susceptible to destabilization. In the opposite, the values for the polydispersity index are 
not significantly different (P > 0.05). Thus knowing the physical characterization of 
liposomes such as size and zeta potential is important and can help to understand the 
fate of the liposomes when undergoing in vivo experiments (Brandl, 2001).  
The encapsulation efficiency achieved for this system was 67%. The values were 
measured by UV-Vis and showed the ability of the liposomes to entrap cholecalciferol, 
since the value is satisfactory.  In literature, several other studies were carried out where 
they show the positive effect of the presence of cholesterol in the drug encapsulation 
(Ramana et. al. 2010). As it is believed that cholecalciferol is incorporated entirely in 
the bilayer, so the encapsulation efficiency is related to the values founded in the 
literature for water-insoluble drugs trapped in the hydrophobic region. Unlike the water 
soluble compounds, the hydrophobic ones are more resistant to loss by diffusion 
resulting in superior values of encapsulation efficiency  (Nii & Ishii, 2005). 
Furthermore, Also it is assumed that hydrophobic substances are efficiently 
incorporated between the bilayer in the preparation process for multilamellar vesicles 
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(Kulkarni & Vargha-Butler, 1995). The results suggest the affinity of the cholecalciferol 
for the liposome membrane. Normally trial and error tests are performed to optimize the 
liposomal encapsulation instead of the investigation of the factors. Although it is 
necessary to take into account the initial conditions both for liposomes and for the drug 
(Kulkarni & Vargha-Butler, 1995).  
 
4.2.2 Stability test 
 
For their successful application as drug carriers, liposomal formulations need to 
be controlled regarding their stability. Liposomes tend to aggregate and fuse which 
results in the loss of the entrapped compound during storage or even during 
administration where his ability is diminished. Another problem that might appear 
during storage for a long period of time is the oxidation of phospholipids that will 
modify the liposome structure (Takeuchi et al., 1998). The physical stability of 
liposomes on storage can be studied by monitoring the size and eventually the zeta 
potential of liposomes. The test was performed to evaluate the physical stability of 
liposomes alone and regarding to the retention of the entrapped content during 3 weeks. 
The physical stability of the liposome was evaluated by measuring the change in 
particle size and zeta potential. The values obtained are shown in the table 5. 
 
Table 5 – Stability test study of unloaded and cholecalciferol-loaded liposomes. Data represented as mean 
± SD (n=10). 
Liposomes Mean diameter (nm) PdI Zeta Potential (mV) 
Unloaded 78.5 ± 0.9 0.09 ± 0.01 -4 ± 1.6 
Cholecalciferol-loaded 78.8 ± 0.6 0.12 ± 0.01 -1 ± 0.9 
 
 
The results obtained for size diameter was approximately 79 ± 0.6 nm in average 
for both formulations and as zeta potential values -4 mV for liposomes alone and 
approximately -1 mV for liposomes loaded with vitamin D. The mean diameter and the 
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PdI values were not statistically significant (P > 0.05), however, the zeta values had 
shown to be significantly different (P < 0.05). Generally, the shelf-life is determined by 
the physical stability where the uniformity of size and minimal degradation of the 
compounds is observed (Sabin et. al. 2006). Besides, the presence of cholesterol in 
liposomes structure is responsible to enhance overall stability, however non-coated 
liposomes are still susceptible to destabilization more easily than the coated ones.  The 
size is an important aspect for stability, where aggregation and fusion are the main 
sources to install instability (Takeuchi et al., 1998). Moreover, the formation of 
liposome aggregates is a natural and is difficult to avoid for neutral liposomes. Besides, 
those physical processes can result in the loss of the cholecalciferol loaded and changes 
in the size. However, liposomes containing phosphatidylcholine (PC) are considered the 
more stable than other type of phospholipids due to their neutral charge (Ulrich, 2002). 
The particle sizes are maintained during the stability control time period which express 
is stability after 3 weeks days in storage and also shows the ability of liposomes to 
incorporate cholecalciferol. It was already observed that liposome vesicles containing 
phosphatidylcholine (PC) with cholesterol exhibit better ability to deal with shear stress. 
Likewise, shown the increase of retention capacity by decreasing the membrane 
permeability which can work as positive or negative feature for drug delivery 
application (Tseng et. al., 2007). Also it is observed change in the zeta potential 
however it remains minimal. A possible explanation is the adsorption of some layer at 
the surface or even the nature composition of the medium in which liposomes are 
suspended during the storage time can cause that minimum change. Usually the zeta 
potential measurement does not play an important role for evaluate the liposomal 
stability except if was possible to control the effects of the applied charge by an 
electronic equipment. In this case the zeta potential is supplementary with the size 
diameter measurements, and should be regarded to support the discussion (du Plessis et 
al., 1996).  
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5 Conclusion and Future Perspectives 
 
5.1 Conclusion 
 
Vitamins have been the subject of interest in several research fields to 
investigate their physiological benefits and methods to preserve their chemical integrity. 
Encapsulation has appeared as a promising approach to protect and take advantage of 
vitamin properties over time. In that order the encapsulation process should provide 
particles with a high encapsulation rate, good polydispersity index, high shelf life, avoid 
possible side effects and providing control delivery into the target. Here vitamin D a 
liposoluble compound was studied which among others has particular anticancer 
properties and it was verified that some limitation exists associated with vitamin D 
encapsulation in the literature. Nanotechnology has been regarded as one of the most 
promising techniques to deal with cancer. Likewise, to provide a solution polymeric 
nanoparticles and liposomes are the two primary choices for nano-carriers for anticancer 
drug delivery. Polymeric nanoparticles has favourable characteristics like small size, 
long circulation half-life, ease of fabrication conditions, controlled release manageable 
and are able to encapsulate drug of poor solubility. The biodegradable polymer selected 
for this study was PLGA, which is already well-known to be used as a drug delivery 
vehicle. On the other hand, liposomes are widely used due to the high biocompatibility 
registered, ease of surface modification and liposomal formulations are already in use as 
anticancer drug for human use. 
In this work, PLGA-based nanoparticles were prepared by the solvent-emulsion 
method. Also was possible to perform the physicochemical and morphologic 
characterization, shown by TEM images, and to verify their behaviour in in vitro 
cytotoxic studies. Cholecalciferol-loaded nanoparticles were produced with a mean 
diameter of approximately 185 nm, as well as a zeta potential value of -29 mV and with 
a encapsulation efficiency near 80%. The concentration-response studies on HPNE cells 
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shown a reduced the cytotoxic effect of the PLGA/vitamin D nanoparticles compared 
with the free vitamin.  
In the other proposed system, liposomes were prepared by the modified thin film 
method. Cholecalciferol-loaded liposomes reveal a mean diameter of 78 nm and the 
values of zeta potential tending to neutral charge. The encapsulation efficiency obtained 
was 67%, revealing the satisfactory uptake of vitamin D by liposomes. Stability studies 
were performed to evaluate the bioavailability and shelf life of the liposomes and 
vitamin D-loaded liposomes. The physical stability was maintained over 3 weeks 
presenting their ability as carrier system. 
 
 
 
5.2 Future Perspectives 
 
There are several experimental tests that after the conclusion of this work could 
had been interesting to perform, but were not possible due to time restrictions.  
The developed work was important to understand the behavioural conditions 
that influence the vitamin D entrapment efficiency for both PLGA nanoparticles and 
liposomes. However, further experimental studies are required to support the knowledge 
of these systems as well as drug loading or process yield. Some other studies may be 
accomplished to evaluate the results such as the change of the polymer ratio or even the 
possibility of coating the particles since some authors defend the coating of PLGA 
nanoparticles. The body recognizes the particles with hydrophobic surfaces as foreign 
and to overcome that limitation the nanoparticles can be coated to have a hydrophilic 
surface. Also is important to study the release profile of the vitamin D nanoparticles by 
dialyses to further application in cancer cells, as well as stability study to fully 
characterize their conditions for long periods of time.  
 Stability tests with the analysis of vitamin D absorbance would be helpful to 
understand if the vitamin is still active inside the liposomes. Moreover, for liposomes a 
morphologic characterization by TEM observation should be performed as well as 
stability tests using differential scanning calorimetry (DSC) and also cytotoxic in vitro 
studies to fully characterize this system. 
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7 Appendix 
A – Cholecalciferol calibration curves 
 
 
 
 
 
 
 
 
 
 
 
Figure 5 - Cholecalciferol calibration curve in ethyl acetate and 0.1% Pluronic F127. Data represented as 
mean (n=3). 
 
 
 
 
 
 
 
 
 
 
 
Figure 6 - Cholecalciferol calibration curve in ethanol. Data represented as mean (n=3).  
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Figure 7 - Cholecalciferol calibration curve in PBS and ethanol (in ratio 1:4). Data represented as mean 
(n=3). 
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